ABL Bio, Inc.

ACTIVE

京畿道城南市, 京畿道, South Koreawww.ablbio.comPublic102 employeesEstablished: 2016-01-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2016

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

100.0%

Trial Status Distribution

Completed

50.0%

Recruiting

50.0%

Clinical Trials

Trials sponsored by this organization (6)

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

interventional

Aug 202565 participants

A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

interventional

Nov 202396 participants

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

Phase 1

Completed

interventional

Dec 202291 participants

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Phase 1

Completed

interventional

Oct 202124 participants

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

interventional

Apr 2021100 participants

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Phase 1

Completed

interventional

Sep 201745 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations